Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.

Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH.

Sci Transl Med. 2011 Aug 10;3(95):95ra73. doi: 10.1126/scitranslmed.3002842.

2.

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

Porter DL, Levine BL, Kalos M, Bagg A, June CH.

N Engl J Med. 2011 Aug 25;365(8):725-33. doi: 10.1056/NEJMoa1103849. Erratum in: N Engl J Med. 2016 Mar 10;374(10):998.

3.

Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity.

Ha SP, Klemen ND, Kinnebrew GH, Brandmaier AG, Marsh J, Hangoc G, Palmer DC, Restifo NP, Cornetta K, Broxmeyer HE, Touloukian CE.

J Clin Invest. 2010 Dec;120(12):4273-88. doi: 10.1172/JCI43274.

4.

Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses.

Koya RC, Mok S, Comin-Anduix B, Chodon T, Radu CG, Nishimura MI, Witte ON, Ribas A.

Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14286-91. doi: 10.1073/pnas.1008300107.

5.

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, Lo RS, Ribas A.

J Transl Med. 2010 Apr 20;8:39. doi: 10.1186/1479-5876-8-39.

6.

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy.

Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A, Kaiser AD, Pouw N, Debets R, Kieback E, Uckert W, Song JY, Haanen JB, Schumacher TN.

Nat Med. 2010 May;16(5):565-70, 1p following 570. doi: 10.1038/nm.2128.

PMID:
20400962
7.

A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model.

Shimizu S, Hong P, Arumugam B, Pokomo L, Boyer J, Koizumi N, Kittipongdaja P, Chen A, Bristol G, Galic Z, Zack JA, Yang O, Chen IS, Lee B, An DS.

Blood. 2010 Feb 25;115(8):1534-44. doi: 10.1182/blood-2009-04-215855.

8.

Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice.

Kitchen SG, Bennett M, Galić Z, Kim J, Xu Q, Young A, Lieberman A, Joseph A, Goldstein H, Ng H, Yang O, Zack JA.

PLoS One. 2009 Dec 7;4(12):e8208. doi: 10.1371/journal.pone.0008208.

9.

Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.

Bobisse S, Rondina M, Merlo A, Tisato V, Mandruzzato S, Amendola M, Naldini L, Willemsen RA, Debets R, Zanovello P, Rosato A.

Cancer Res. 2009 Dec 15;69(24):9385-94. doi: 10.1158/0008-5472.CAN-09-0494.

10.

Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen.

Shu CJ, Radu CG, Shelly SM, Vo DD, Prins R, Ribas A, Phelps ME, Witte ON.

Int Immunol. 2009 Feb;21(2):155-65. doi: 10.1093/intimm/dxn133.

11.

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA.

J Clin Oncol. 2008 Nov 10;26(32):5233-9. doi: 10.1200/JCO.2008.16.5449.

12.

Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitors.

van Lent AU, Nagasawa M, van Loenen MM, Schotte R, Schumacher TN, Heemskerk MH, Spits H, Legrand N.

J Immunol. 2007 Oct 15;179(8):4959-68.

13.

Immune-cell lineage commitment: translation from mice to humans.

Payne KJ, Crooks GM.

Immunity. 2007 Jun;26(6):674-7.

14.

Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling.

Zhao Y, Parkhurst MR, Zheng Z, Cohen CJ, Riley JP, Gattinoni L, Restifo NP, Rosenberg SA, Morgan RA.

Cancer Res. 2007 Mar 15;67(6):2425-9.

15.

Improving T cell therapy for cancer.

Leen AM, Rooney CM, Foster AE.

Annu Rev Immunol. 2007;25:243-65. Review.

PMID:
17129181
16.

Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1.

Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, Othieno FA, Wege AK, Haase AT, Garcia JV.

Nat Med. 2006 Nov;12(11):1316-22.

PMID:
17057712
17.

Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.

Johnson LA, Heemskerk B, Powell DJ Jr, Cohen CJ, Morgan RA, Dudley ME, Robbins PF, Rosenberg SA.

J Immunol. 2006 Nov 1;177(9):6548-59.

18.

Cancer regression in patients after transfer of genetically engineered lymphocytes.

Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA.

Science. 2006 Oct 6;314(5796):126-9.

19.

CD8+ T-cell memory in tumor immunology and immunotherapy.

Klebanoff CA, Gattinoni L, Restifo NP.

Immunol Rev. 2006 Jun;211:214-24. Review.

20.
Items per page

Supplemental Content

Support Center